Novartis Cosentyx Receives EU Approval for First-line Systemic Treatment in Pediatric Psoriasis
Novartis (NYSE: NVS) today announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years.
Benzinga · 13分钟前
时代医药周报 | 第三批国采规则变动较小，市场预期趋于稳定
时代周报 · 6小时前
The Market Continues to Undervalue AbbVie
GuruFocus.com · 12小时前
Checkmate Pharmaceuticals Begins IPO Process
Seeking Alpha · 2天前
China to add 56 drugs to price-slashing bulk-buy programme
China has added 56 medicines, including some global blockbuster drugs, to its state bidding programme aimed at procuring key treatments at big discounts in return for offering large-volume state contracts, a state agency said. The procurement authorities rele
Reuters · 3天前
7 Biopharmaceutical Companies Finding Success During COVID-19
CorpGov.com · 3天前
康希诺生物回归A股登陆科创板 疫苗龙头在研品种丰富
证券时报 · 3天前
Sangamo, Novartis Make Gene Therapy Deal for Brain Disorders